All In Biotech

Drug Trial Radar · NCT06117566

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 18, 2022

Primary completion

Nov 9, 2025

Study completion Nov 9, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors. The main questions it aims to answer are: * the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390; * safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.

Conditions

  • Solid Tumor

Interventions

  • WX390Drug

    WX390 tablet, once a day

  • ToripalimabDrug

    240 mg, Day 1, every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in DLT observation periodTime frame: up to 24 weeks
  2. Progression-free survival rate (PFS rate)Time frame: up to 24 weeks
  3. Objective response rate (ORR)Time frame: up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the first affiliated hospital of Jilin university

    Changchun, Jilin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.